47 Avenue Road
56 articles with Portage Biotech
Portage Announces Increase in Holdings of Portfolio Company, Intensity Therapeutics With Positive Business, Regulatory, & Clinical Updates
Portage Biotech Inc., ("Portage" or the "Company") (CSE: PBT.U, OTC Markets: PTGEF) today announced it has entered in an agreement with Fast Forward Innovations Limited (AIM Market: FFWD) ("Fast Forward") to purchase Intensity Holdings Limited ("IHL"), a wholly-owned subsidiary of fast forward.
The Board of Directors of Portage Biotech Inc announces that Dr. Declan Doogan, the current Chief Executive Officer ("CEO") has decided to step down with immediate effect.
Portage Biotech Inc., is pleased to announce that it has made an additional €600k investment in its associate, Stimunity, the Paris-based cancer immunotherapy company focused on STING.
Portage Biotech Inc. announces that it has changed its auditors from Swartz Lewisky Feldman LLP to Marcum LLP effective immediately.
Portage Biotech Inc. wishes to announce that due to an oversight, closing of the SalvaRx Acquisition was completed prior to obtaining final CSE approval.
FINRA also imposed trading halt on our shares on OTC Market.
Portage Provides Additional Information Relating to the Independent Director Review of the Proposed Acquisition of SalvaRx Limited
The purpose of this press release is to provide supplemental disclosure to the Corporation's management information circular and proxy statement dated November 26, 2018 in respect of the Annual and Special Meeting of the Shareholders of the Corporation to be held at 10:00 am (Toronto time) on January 8, 2019.
iOx Therapeutics is a United Kingdom-based immuno-oncology company.
Portage posts meeting materials; trading on CSE expected to resume shortly; overview of combined Portage/SalvaRx portfolio
Further to its news release of November 21, 2018, Portage Biotech Inc. is very pleased to announce that it has published and posted its shareholder meeting materials which provide information regarding the rationale and key business terms for the proposed acquisition of SalvaRx Limited ("SalvaRx") from SalvaRx Group plc
The meeting is scheduled for January 8th, 2019 for shareholders of record as of November 23, 2018.
Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a SalvaRx Limited portfolio company, Intensity Therapeutics, Inc. ("Intensity"). SalvaRx Limited holds an 8.5% equity interest in Intensity.
Portage Biotech Inc. ("Portage" or the "Company") wishes to announce that, further to its news release of August 14, 2018 announcing the proposed acquisition of SalvaRx Limited from SalvaRx Group plc, it has now submitted draft shareholder meeting materials to CSE for review.
Portage Biotech Inc. is pleased to announce that the US Patent Office has granted Stimunity its main patent, US2016/074507, entitled "Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response."
Portage will invest US$950,000 by subscribing to an unsecured, one-year convertible loan instrument.
Stimunity will use the proceeds of this seed round to fund the preclinical development of its lead product, a potent biologic enhancer of the STING pathway that activates the immune system against tumor cells.
Portage Pharmaceuticals is providing an undisclosed funding to the new business along with a limited license to its CellPorter peptide delivery technology.
Portage Biotech is pleased to announce that it has completed the distribution of shares of Biohaven Pharma to all eligible Portage shareholders.
Portage Biotech announces that trading in PBT.U was halted this morning pending clarification by the Canadian Securties Exchange of the Record Date and ex-distribution date.
This statement is provided for shareholders who are United States persons for purposes of the U.S. Internal Revenue Code of 1986, as amended and the related United States Treasury regulations.
Portage Biotech plans to distribute as stock dividend, a substantial part of the 6,341,500 common shares it holds in Biohaven Pharma.